Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.24.0.1
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
item
Oct. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Licensing and other arrangements              
Revenue from contracts with customers       $ 2,650 $ 4,150    
Novartis Note              
Licensing and other arrangements              
Reduction in debt obligation     $ 7,300        
Novartis International | License Agreement              
Licensing and other arrangements              
Agreement termination prior written notice period 180 days            
Number of performance obligations | item 1            
Cash payment received     17,700       $ 37,000
Revenue from contracts with customers   $ 35,000 $ 25,000 0 0 $ 10,000 $ 37,000
Maximum eligible milestone payments receivable $ 480,000            
Minimum period eligible to receive royalties 10 years            
Contract assets       0 0    
Contract liabilities       0 0    
Capitalized contract costs       $ 0 $ 0